Suche
Mein Konto
DOAC use is associated with a lower risk of renal complications in patients with atrial fibrillation
A Swedish cohort study shows a 13% (95% CI, 2-22%) lower risk of worsening renal function or renal failure and a 12% (95% CI, 3-20%) lower risk of acute kidney injury using direct oral anticoagulants vs. vitamin K antagonists in non-valvular Atrial fibrillation. The relative safety of anticoagulation with direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs) is still unclear, particularly with regard to renal outcomes. In a cohort of patients with non-valvular atrial fibrillation from Sweden, researchers observed that DOAC initiation was associated with a lower risk of the combination of renal failure and persistent...
DOAC use is associated with a lower risk of renal complications in patients with atrial fibrillation
A Swedish cohort study shows a 13% (95% CI, 2-22%) lower risk of worsening renal function or renal failure and a 12% (95% CI, 3-20%) lower risk of acute kidney injury using direct oral anticoagulants vs. vitamin K antagonists in non-valvular Atrial fibrillation.
The relative safety of anticoagulation with direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs) is still unclear, particularly with regard to renal outcomes. In a cohort of patients with non-valvular atrial fibrillation from Sweden, researchers observed that DOAC initiation was associated with a lower risk of the combination of renal failure and sustained eGFR decline by 30% compared to VKA, as well as a lower risk of AKI occurrence.
Consistent with study results, DOAC treatment was associated with a lower risk of major bleeding compared to VKA treatment, but a similar risk of the composite of stroke, systemic embolism, or death. Overall, these results, recently published in the American Journal of Kidney Diseases (AJKD), add new evidence on the safety and effectiveness of DOACs in atrial fibrillation.
Source:
Reference:
Trevisan, M., et al. (2022) Cardiorenal outcomes in patients with atrial fibrillation treated with oral anticoagulants. American Journal of Kidney Diseases. doi.org/10.1053/j.ajkd.2022.07.017.
.